UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative...
Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN FRANCISCO, Aug. 26, 2019...
true0001628738 0001628738 2019-06-07 2019-06-07 UNITED STATES SECURITIES AND EXCHANGE...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
false--12-31Q2201900016287381420100029200016950000.000010.0000130000000030000000043546786453841114354678645384111000000.000010.000011000000010...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Commenced...
Audentes Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN FRANCISCO, Aug. 1, 2019...
Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on...
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.